Key result
First-line doxorubicin-based immunochemotherapy for non-Hodgkin lymphoma was associated with at least one anthracycline-related cardiovascular event in 11.1% of patients.
Why the study?
The study was conducted to assess cardiovascular toxicity and treatment discontinuation for cardiovascular toxicity in patients with DLBCL or FL treated with R-CHOP-like immunochemotherapy.
What is the incidence and risk profile of cardiovascular toxicity in patients with non-Hodgkin lymphoma treated with first-line doxorubicin-based chemotherapy?
Cohort (n=433)
No
What is the incidence and risk profile of cardiovascular toxicity in patients with non-Hodgkin lymphoma treated with first-line doxorubicin-based chemotherapy?
First-line doxorubicin-based chemotherapy for non-Hodgkin lymphoma carries an 11.1% risk of cardiovascular toxicity, which is significantly higher in patients with pre-existing ischemic or valvular heart disease.
Prior IHD or valvular disease associated with higher anthracycline CV risk in lymphoma; leaves open whether risk-stratified regimens improve outcomes.
We conducted a single-center retrospective study to assess cardiovascular (CV) toxicity and treatment discontinuation for CV toxicity in diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) patients treated with immunochemotherapy (R-CHOP-like). Between 2006 and 2017, 433 patients were included (DLBCL: n = 345, FL: n = 88). The median age was 63 years (50–73). We defined three types of CV toxicity: early-onset cardiovascular toxicity (the event occurred within 6 months following treatment start); subacute toxicity (the event occurred between 6 months and 1 year after treatment start) and late toxicity (the event occurred 1 year or more after treatment start). Forty-eight (11.1%) patients experienced at least one anthracycline-related CV event. Seven patients experienced treatment discontinuation due to CV toxicity. Early-onset and subacute cardiac events were primarily acute heart failure (34.3%) and atrial fibrillation (28.6%). History of ischemic heart disease (p = 0.02) and valvular heart disease (p = 0.03) were associated with a higher risk of anthracycline-related CV event occurrence.
No takes yet. Share an insight, caveat, or question.
Zduniak et al. (2022) conducted a cohort in Non-Hodgkin lymphoma (diffuse large B-cell lymphoma or follicular lymphoma) (n=433). First-line doxorubicin-based immunochemotherapy (R-CHOP-like) was evaluated on Anthracycline-related cardiovascular event. First-line doxorubicin-based immunochemotherapy for non-Hodgkin lymphoma was associated with at least one anthracycline-related cardiovascular event in 11.1% of patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: